Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials
Authors
Keywords
Antiangiogenic drug, Bevacizumab, Interstitial lung disease, Chemotherapy
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 174, Issue -, Pages 103703
Publisher
Elsevier BV
Online
2022-05-07
DOI
10.1016/j.critrevonc.2022.103703
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment
- (2022) P. Conte et al. ESMO Open
- Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
- (2021) Hiroaki Akamatsu et al. JAMA Oncology
- Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia?
- (2021) Elisabetta A Renzoni et al. LANCET
- Anti-VEGF antibody protects against alveolar exudate leakage caused by vascular hyperpermeability, resulting in mitigation of pneumonitis induced by immunotherapy
- (2021) Toshiki Iwai et al. MOLECULAR CANCER THERAPEUTICS
- Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
- (2021) Paolo Tarantino et al. JAMA Oncology
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
- (2020) Josep Garcia et al. CANCER TREATMENT REVIEWS
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
- (2019) Haruhiro Saito et al. LANCET ONCOLOGY
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
- (2019) Oliver Distler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
- (2019) Shohei Hamada et al. BMC Pulmonary Medicine
- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
- (2019) Kevin R. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
- (2018) Shaney Barratt et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lung cancer and interstitial lung disease: a literature review
- (2018) Jean-Marc Naccache et al. Journal of Thoracic Disease
- Drug-Induced Interstitial Lung Disease: A Systematic Review
- (2018) Sarah Skeoch et al. Journal of Clinical Medicine
- The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials
- (2017) Giandomenico Roviello et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
- (2017) Heather A Wakelee et al. LANCET ONCOLOGY
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Lesley A. Stewart et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Vascular Endothelial Growth Factor in Recovery Phase of Acute Lung Injury in Mice
- (2015) Junfeng Song et al. LUNG
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
- (2012) Seiji Niho et al. LUNG CANCER
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
- (2011) Roy S Herbst et al. LANCET
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now